首页> 外国专利> METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY

METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY

机译:预测血清尿酸尿酸期间预测输液反应风险和抗体介导的响应丧失的方法和试剂盒

摘要

Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
机译:提供了用于预测输注反应风险和抗体介导的痛风患者静脉内聚乙二醇化尿精治疗期间的抗体介导的响应丧失的方法和试剂盒。常规SUA监测可用于鉴定接受PEG化尿精组酶的患者,他们可能不再受益于治疗,并且患者更大的输液反应风险。

著录项

  • 公开/公告号US2021181187A1

    专利类型

  • 公开/公告日2021-06-17

    原文格式PDF

  • 申请/专利权人 HORIZON PHARMA RHEUMATOLOGY LLC;

    申请/专利号US202017036110

  • 发明设计人 THERESA ROSARIO-JANSEN;DAVID ERICK WRIGHT;

    申请日2020-09-29

  • 分类号G01N33/53;G01N33/68;A61K47/60;A61P19/02;A61K9;A61K38/44;

  • 国家 US

  • 入库时间 2022-08-24 19:23:57

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号